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ABSTRACT We present here a computational, rule-based model to study the function of the SH2 domain-containing protein
tyrosine phosphatase, Shp2, in intracellular signal transduction. The two SH2 domains of Shp2 differentially regulate the
enzymatic activity by a well-characterized mechanism, but they also affect the targeting of Shp2 to signaling receptors in cells.
Our kinetic model integrates these potentially competing effects by considering the intra- and intermolecular interactions of the
Shp2 SH2 domains and catalytic site as well as the effect of Shp2 phosphorylation. Even for the isolated Shp2/receptor system,
which may seem simple by certain standards, we ﬁnd that the network of possible binding and phosphorylation states is
composed of over 1000 members. To our knowledge, this is the ﬁrst kinetic model to fully consider the modular, multifunctional
structure of a signaling protein, and the computational approach should be generally applicable to other complex intermolecular
interactions.
INTRODUCTION
Intracellular signal transduction pathways mediated by
growth factor, cytokine, and hormone receptors control cell
behavior, such as proliferation, survival, migration, and
differentiation. Protein tyrosine kinases, including growth
factor receptors of the receptor tyrosine kinase (RTK) class,
catalyze tyrosine phosphorylation and are typically involved
in the initial steps of signal transduction, but equally im-
portant in determining the magnitude and kinetics of the
intracellular response are the opposing tyrosine dephosphor-
ylation reactions, catalyzed by protein tyrosine phospha-
tases (PTPs) (1). In RTK signaling, the ligated receptors
dimerize such that their intracellular tails may be trans-
phosphorylated on speciﬁc tyrosine residues, which then act
as a scaffold for the binding of cytosolic signaling proteins
with Src homology 2 (SH2) and other phosphotyrosine-
binding domains. These proteins include certain enzymes,
adaptor proteins, and transcription factors, which may be
activated upon binding to the receptor complex and/or by
subsequent phosphorylation, dephosphorylation, or other
modiﬁcations (2,3). In general, the modular design of sig-
naling proteins, typically composed of multiple domains
with speciﬁc functions, is a central paradigm in the under-
standing of signal transduction networks; how these domains
work together in the full-length protein, and in the context of
signaling mediated by certain receptors, is a problem steeped
in complexity (4–6).
In this work, we analyze the function of one such signaling
protein, SH2 domain-containing phosphatase (Shp) 2. Shp2
and the closely related Shp1 are intriguing because each has
a classic PTP catalytic domain as well as two SH2 domains
that regulate its activity and help target the enzyme to phos-
phorylated RTKs and other tyrosine-phosphorylated proteins
(7). Whereas most PTPs are thought to simply antagonize
RTK signaling, Shp2 plays a positive role in the activation of
the Ras/extracellular signal-regulated kinase (Erk) signaling
cascade mediated by platelet-derived growth factor (PDGF)
receptors, epidermal growth factor (EGF) receptor, and other
RTKs. A candidate mechanism for this effect is the dephos-
phorylation of the tyrosine residues in PDGF and EGF
receptors that bind Ras GTPase-accelerating protein, a neg-
ative regulator of Ras activation; these residues are distinct
from those that engage the SH2 domains of Shp2 (8–10).
The precise dephosphorylation targets and signaling roles of
Shp2 in cells have yet to be fully elucidated, however.
The structure of Shp2 and its relationship to the regulation
of catalytic activity, at least in solution, are relatively well
understood. The crystal structure of Shp2 clearly shows an
autoinhibition of the PTP catalytic site by the N-terminal
SH2 domain (N-SH2), whereas the more C-terminal SH2
domain (C-SH2) does not interact in this way (11,12). The
autoinhibited, ‘‘closed’’ conformation is highly favored
under basal conditions. Binding of the N-SH2 domain to a
phosphotyrosine-containing protein stabilizes the ‘‘open’’
conformation of Shp2, activating the enzyme. In solution,
addition of small, phosphorylated peptide sequences mim-
icking SH2 binding sites leads to a .10-fold increase in
Shp2 enzyme activity, and a variant with the N-SH2 domain
deleted exhibits an even higher activity that is not augmented
further by phosphopeptide addition (13–16). A notable
caveat in such studies is that, at least in certain cases, N-SH2-
binding peptides can also be dephosphorylated by the PTP
active site, requiring a more sophisticated biochemical
analysis (17). Consistent with the crystal structure, deletion
of the C-SH2 domain does not activate the enzyme, nor does
it inﬂuence enzyme activation by N-SH2-binding peptides in
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solution; however, C-SH2 deletion does reduce the potency
of synthetic peptides bearing two SH2 domain-binding
phosphotyrosines, suggesting that the N-SH2 and C-SH2
domains bind such peptides and multiply phosphorylated
protein complexes in a synergistic manner to better stabilize
the open form of Shp2 (16,18–21).
Shp2 is also subject to tyrosine phosphorylation on two
sites near its C-terminus in response to growth factor stim-
ulation (22,23). Mutating these sites to phenylalanine leads
to a modest reduction in Erk signaling (24), suggesting that
Shp2 phosphorylation plays a role in enzyme activation.
Selective attachment of chemical moieties that mimic the
effects of phosphate addition yields higher Shp2 activity in
solution and when microinjected into cells (25–27), and a
conceptual model has emerged in which the N-SH2 domain,
alone or in tandem with the C-SH2 domain, are engaged by
the C-terminal phosphorylation sites in the same molecule.
This hypothesis remains controversial because it cannot be
directly tested (Shp2 dephosphorylates itself in solution) and
because the phosphorylation site(s) can serve an adaptor
function that might affect Ras activation (28,29).
The complexity of signal transduction has motivated the
use of quantitative, mathematical modeling approaches in
recent years to better understand the kinetic mechanisms
involved and how they might work in concert inside the cell.
Modeling can be a powerful tool for analysis, but an appro-
priate balance must always be struck between the inclusion
of known signaling interactions and the tractability of the
model (30,31). As one adds protein binding and phospho-
rylation states to the model, the number of species increases
dramatically, an issue termed ‘‘combinatorial complexity’’
(32). Even in the early stages of intracellular signaling, in
which the formation of receptor complexes may be governed
by just a handful of simple binding rules (e.g., a cytosolic
protein may associate with a receptor if a speciﬁc receptor
site is phosphorylated and unoccupied), the number of dif-
ferent combinations of protein states can easily reach the
hundreds or thousands, as seen in the recent model of FceRI
signaling (33). Computational tools for rule-based modeling,
which generate the network of rate processes and construct
the governing equations automatically, are becoming in-
creasingly available (34–37).
In this work, we have constructed a rule-based kinetic
model of the interactions between Shp2 and a dimerized
RTK, although the analysis may be generalized to the
interactions of Shp2 or Shp1 with other multiprotein com-
plexes. Among other effects, we have systematically ana-
lyzed the dual role of the Shp2 SH2 domains; on the one
hand, they regulate the enzymatic activity, as characterized
in solution, while on the other hand, they target the enzyme
to receptor complexes in cells. The latter inﬂuences the
activity toward substrates in the complex through an induced
proximity effect, as considered in our previous model of PTP
regulation (38). Accordingly, in the context of the currently
accepted mechanisms of Shp2 regulation, we ﬁnd regimes
of receptor-Shp2 binding where N-SH2 deletion or C-terminal
phosphorylation of Shp2 would either diminish or enhance
receptor dephosphorylation, whereas deletion of the C-SH2
domain or both SH2 domains unilaterally impairs this function.
MATERIALS AND METHODS
Structure-based kinetic model of Shp2 regulation
and function
In our models, activated receptors and Shp2 molecules are present at total
concentrations of Rtot and Stot, respectively, calculated on the basis of the
cytosol volume. For the sake of simplicity, we introduce activated receptors
as preformed dimers (dimer concentration is Rtot/2) and do not include the
processes of external receptor-ligand binding and dimer association/
dissociation. We are concerned only with the steady-state behavior, and a
dose response curve is implied by performing model calculations with
different values of Rtot (38). The hypothetical receptor has two phospho-
rylation sites: Y1 is a substrate of the Shp2 catalytic (PTP) domain, and
Y2 engages SH2 domains of Shp2 and is always phosphorylated in our model.
In the human PDGF b-receptor, Y1 and Y2 would correspond to Tyr-771 and
Tyr-1009, for example (8,9,13,39). The assumed binding/modiﬁcation rules
are illustrated in Fig. 1 and are summarized as follows; base-case rate
constant values are given in Table 1.
Shp2 is autoinhibited through the reversible association of its N-SH2 and
PTP domains (the closed conformation), provided that neither domain is
receptor bound. From thermodynamic constraints, it follows that neither the
N-SH2 nor PTP domain can engage receptor sites when Shp2 is in the closed
conformation (11), whereas it is assumed that binding the C-SH2 domain to
receptors is not affected by the transition between open and closed con-
formations (Fig. 1 a). Phosphorylation of receptor Y1 sites by the intrinsic
kinase activity is modeled as a single, unimolecular step, as considered in
previous models (33,40), whereas dephosphorylation of Y1 by Shp2 is
modeled with explicit accounting of the enzyme-substrate interaction and
catalytic step (Fig. 1 b).
Once an Shp2 molecule is recruited from the cytosol to an activated
receptor complex, its free SH2 and/or PTP domains may associate with free
phosphotyrosine sites in the complex. As has been suggested in the literature
for PDGF b-receptor (20), we allow the two SH2 domains of Shp2 to bridge
the two Y2 sites in the receptor dimer. Such ring closure transitions are
unimolecular, and their rate constants are calculated by multiplying the
second-order rate constants characterizing the corresponding bimolecular
associations by various conversion factors xr, which have units of concen-
tration and ensure that microscopic reversibility is satisﬁed (38). If one were
to assume that binding partners in the same complex are conﬁned within
a volume of 100 nm3 (1020 L), the concentration of a single molecule in
that volume is ;10 mM; this is a reasonable estimate of xr, although its
value might be signiﬁcantly increased or decreased subject to orientation
constraints. The model here allows different values of xr for different
interactions but also recognizes that not all of these values are independent.
There are ﬁve types of complexes with two Shp2 domains bound (Fig. 1 c)
and two types of complexes with all three Shp2 domains occupied (Fig. 1 d);
the overall equilibrium constant for the formation of a complex requir-
ing multiple steps does not depend on the order of the steps, and seven
independent xr factors were identiﬁed and assigned conservative base-
case values of 0.1 or 1 mM (Table 2, and Fig. S1 of the Supplementary
Material). One might take as a base assumption that all such factors have
the same value, as considered previously (38), but we arbitrarily assigned
one of two different values for each binding mode to illustrate the ﬂex-
ibility of the model. Finally, for simplicity we neglect the formation of
chains containing more than one dimer. We found that the large number of
combinations of lateral association and ring closure interactions involving
such complexes, even when limited to species containing only two dimers,
makes the model intractable. Even with all of its limiting assumptions, the
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model described above is composed of 149 distinct species participating in
1,032 reactions.
The base model was extended to consider the phosphorylation of Shp2 on
a single tyrosine site, which can occur only when Shp2 is receptor bound. In
the phosphorylated state, this site can reversibly engage the N-SH2 domain
of the same molecule, provided that the N-SH2 is free and in the open
conformation. This interaction maintains the PTP in the open conformation
but also prevents Shp2 association with receptors via N-SH2. Dephospho-
rylation of the Shp2 phosphorylation site, when not occupied by N-SH2, can
occur anywhere in the cell and is modeled simply as a unimolecular
transition (Fig. 1 e). Adding these simple rules increased the complexity of
the system by an order of magnitude, yielding a model with 1,325 species
and 15,284 reactions.
Implementation of rule-based models
The binding and reaction rules and their associated rate constants were
speciﬁed in the syntax of the second-generation version of BioNetGen (34),
BioNetGen2, which uses graph theoretic methods to automatically generate
the associated network of kinetic balances (ordinary differential equations
in time). The open-source software (available through http://bionetgen.lanl.
gov) uses standard numerical algorithms to solve the generated system of
equations, which was deemed to be at steady state at time ¼ 103 s. The anno-
tated input ﬁles for the base and Shp2 phosphorylation models (Shp2_base.bngl
and Shp2_extended.bngl, respectively), which specify the binding/reaction
rules, and a detailed description of the BioNetGen2 syntax (TextS1.pdf) are
provided as Supplementary Material.
Simpliﬁed kinetic model
The simplest model of Shp2/receptor interaction treats SH2 domain-
mediated binding of cytosolic Shp2 (S) to receptor dimers as a one-step
process, with effective forward and reverse rate constants k1 and k,
respectively. Shp2 binding is assumed here to be independent of the
phosphorylation state of the Shp2 substrate site, which is phosphorylated by
the intrinsic kinase with rate constant kkin and, when Shp2 is bound,
FIGURE 1 Kinetic model of Shp2 struc-
ture-function in receptor signaling. The
hypothetical signaling complex contains
two activated, dimerized receptors (blue),
each with two tyrosine phosphorylation
sites considered: phosphorylated Y1 is a
substrate of the Shp2 catalytic PTP domain
(red), whereas phosphorylated Y2 engages
either SH2 domain (green) of Shp2. (a)
Recruitment of Shp2 from the cytosol. The
PTP and N-SH2 domains may only bind
receptors when they are in the ‘‘open’’
conformation. (b) Phosphorylation and
Shp2-mediated dephosphorylation of the
receptor Y1 site. (c) The ﬁve types of
complexes with two Shp2 domains en-
gaged by receptor sites. (d) The two types
of complexes with three Shp2 domains
engaged by receptor sites. (e) Receptor-
mediated phosphorylation of Shp2 favors
the open PTP conformation by occupying
the N-SH2 domain.
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dephosphorylated with effective rate constant kPTP. D and D* denote
receptor dimers free for Shp2 binding and in the unphosphorylated and
phosphorylated states, respectively, and DS and D*S denote the correspond-
ing species with Shp2 bound. We deﬁne Dtot as the total concentration of
dimers, according to
Dtot ¼ D1D1DS1DS: (1)
The bound fraction, bD, and phosphorylated fraction, pD, are deﬁned as
bD ¼ DS1D

S
Dtot
; pD ¼ D
1DS
Dtot
: (2)
At steady state, the simpliﬁed model gives the following relationship
between pD and bD,
pD ¼ f 1 QbD½11 ð1 fÞð1 bDÞ
fð1 bDÞ1 ð1 QÞbD
 
;
f ¼ kkin
kkin1 kPTP
; Q ¼ kkin1 kPTP
k1 kkin1 kPTP
:
(3)
As in the analysis of related models (40,41), this relationship is cast in
terms of two constant parameters: f, which compares the rates of phos-
phorylation and dephosphorylation when Shp2 is bound (accordingly,
pD ¼ f when bD ¼ 1), and Q, the exchange quotient. When Q  1
(slow exchange), all dimers not bound to Shp2 remain phosphorylated,
whereas a fraction f of the Shp2-bound dimers are phosphorylated, such
that pD  1 ð1 fÞbD. In the limit of Q  0 (rapid exchange), the
frequency of dephosphorylation on all receptors approaches bDkPTP, and
thus pD  kkin=ðkkin1bDkPTPÞ ¼ f=½f1ð1 fÞbD.
RESULTS
Shp2 targeting to receptor complexes:
multivalency and serial engagement
The function of Shp2 is quantiﬁed in terms of the fraction of
receptor sites Y1 that are phosphorylated (pYR/Rtot) at steady
state; lower values indicate greater overall rates of Shp2-
mediated dephosphorylation. The quasi-steady-state approx-
imation is valid when there is a disparity in timescales
between that of the intracellular processes (seconds) and that
of the binding/trafﬁcking processes that govern the total
number of dimerized receptors (minutes), as considered
previously (38,40).
Using the base model, we ﬁrst systematically varied the
concentrations of activated receptors and Shp2 and the bind-
ing afﬁnities of the Shp2 SH2 domains (Fig. 2). The concen-
tration of receptors in dimers (Rtot) was varied in the range of
0.05–0.5 mM (cytosolic volume basis, or 3 3 104 – 3 3 105
molecules/pL), whereas the concentration of Shp2 (Stot) was
assigned a value of 0.05, 0.1, or 0.2 mM. These receptor and
Shp2 concentrations are in the general range of values that are
typical of intracellular signaling proteins. Also varied was the
dissociation rate constant koff of the SH2 domain-receptor
interactions, assumed to be equivalent for the C-SH2 and
N-SH2 domains. The values are such that the single-site
dissociation constants, KD, are in the range of 0.1–10 mM,
which spans the range of highly speciﬁc and regulatory SH2-
phosphotyrosine interactions (20,42). As expected, essentially
all dimers are bound with Shp2 when the afﬁnity is suf-
ﬁciently high (low koff) and Shp2 outnumbers activated
receptors (Rtot/2Stot , 1); this yields the minimum extent of
receptor phosphorylation (Fig. 2). As the SH2 domain af-
ﬁnities are decreased, Shp2-receptor binding decreases dra-
matically, because both SH2 domains are affected.
The fraction of phosphorylated receptors tends to increase
as the number of activated receptors is increased, which
saturates the binding of Shp2. When activated receptors
greatly outnumber Shp2 molecules, a higher dissociation rate
from receptors can actually be advantageous. This is a man-
ifestation of the serial engagement effect, more commonly
associated with T-cell receptor activation (43–45), whereby
one molecule of Shp2 encounters and dephosphorylates
multiple dimers before the kinase activity can restore their
phosphorylation. Indeed, model calculations show that,
when activated receptors are relatively abundant, there is a
TABLE 1 Base-case values of rate constants used in
model calculations
Rate constant Base value(s)
kopen 10 s
1
kclose 500 s
1
kon,CSH2 ¼ kon,NSH2 1 mM1s1 (58)
koff,CSH2 ¼ koff,NSH2 0.1–10 s1 (20,42)
kon,PTP 1 mM
1s1 (58)
koff,PTP 10 s
1 (14,59)
kcat,PTP 1 s
1 (14,59)
kkin,Y1 0.1 s
1
kkin,Shp2* 1 s
1
kdePO4* 1 s
1
kon,PO4* 100 s
1
koff,PO4* 0.1 s
1
*Only applicable to the extended model, presented in Fig. 5.
TABLE 2 Conversion factors for intracomplex binding
of Shp2 domains
Order of binding xr factors (value in mM)
C-Y2; N-Y29; P-Y1 xr1 (10
3); xr6 (10
2)
C-Y2; N-Y29; P-Y19 xr1 (10
3); xr7 (10
2)
C-Y2; P-Y1; N-Y29 xr2 (10
2); xr8 ¼ xr1xr6/xr2
C-Y2; P-Y19; N-Y29 xr3 (10
3); xr9 ¼ xr1xr7/xr3
N-Y29; C-Y2; P-Y1 xr1 (10
3); xr6 (10
2)
N-Y29; C-Y2; P-Y19 xr1 (10
3); xr7 (10
2)
N-Y29; P-Y1; C-Y2 xr4 (10
3); xr10 ¼ xr1xr6/xr4
N-Y29; P-Y19; C-Y2 xr5 (10
2); xr11 ¼ xr1xr7/xr5
P-Y1; C-Y2; N-Y29 xr2 (10
2); xr8 ¼ xr1xr6/xr2
P-Y19; C-Y2; N-Y29 xr3 (10
3); xr9 ¼ xr1xr7/xr3
P-Y1; N-Y29; C-Y2 xr4 (10
3); xr10 ¼ xr1xr6/xr4
P-Y19; N-Y29; C-Y2 xr5 (10
2); xr11 ¼ xr1xr7/xr5
Each row lists one of the 12 ways all three receptor-binding domains of
Shp2 (C, C-SH2; N, N-SH2; P, PTP) may be sequentially engaged. The
receptor site that ultimately engages C-SH2 is denoted Y2, and Y1 is the
Shp2 substrate site on that receptor; the receptor site that ultimately engages
N-SH2 is denoted Y29, and Y19 is the Shp2 substrate site on that receptor.
The right-hand column speciﬁes the conversion factors, xr, applied to the
second and third steps of the complex formation (see also Fig. S1 of the
Supplementary Material).
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value of koff that maximizes the extent of receptor dephos-
phorylation (Fig. 2 a and b; high Rtot, koff  1–3 s1).
The serial engagement effect can be understood in the
context of a simple kinetic model in which the association
and dissociation of Shp2 from receptor complexes and Shp2-
mediated dephosphorylation of receptors are approximated
as single steps (Fig. 3). In this model, the potential for serial
engagement is encapsulated in a single dimensionless param-
eter, the exchange quotient Q that characterizes the number
of phosphorylation and dephosphorylation reactions that
occur during the lifetime of an Shp2/receptor encounter
(Eq. 3, Materials and Methods). When Q  1, all activated
receptors not bound to Shp2 are maintained in a fully phos-
phorylated state, whereas a value of Q signiﬁcantly ,1 is
indicative of serial engagement and its degree. As a function
of the fraction of dimers bound, bD, a lower value of Q
always improves the overall rate of dephosphorylation. This
is evident when the results from Fig. 2 are plotted in this way
and compared with the predictions of the simpliﬁed kinetic
model: increasing the SH2 domain dissociation constant
decreases the average lifetime of the Shp2/receptor associ-
ation, decreasing the apparent value ofQ and enhancing serial
engagement (Fig. 3).
Intracomplex binding, controlled by the magnitudes of the
conversion factors xr, is critical for high-avidity binding of
Shp2 (Fig. 4). Increasing the rates of intracomplex binding
affects Shp2 function in the same manner as decreasing koff
and can offset a reduction in the afﬁnities of the individual
SH2 domains. Both parameters inﬂuence the average rate
of Shp2 dissociation from the receptor complex, which was
FIGURE 2 Steady-state analysis of Shp2-mediated receptor dephospho-
rylation. The fraction of activated receptors phosphorylated on the Shp2 sub-
strate site, Y1 (pYR/Rtot), was calculated as a function of the abundance of
activated receptors, mimicking a dose response or varying expression levels
(Rtot), and the binding afﬁnities of the two Shp2 SH2 domains (varied in terms
of the dissociation rate constant, koff,CSH2 ¼ koff,NSH2 ¼ koff). The other var-
iable is the abundance of Shp2 (Stot): (a) Stot ¼ 0.05 mM; (b) Stot ¼ 0.10 mM;
(c) Stot ¼ 0.20 mM. All other rate constants are as listed in Tables 1 and 2.
FIGURE 3 Serial engagement of activated receptors by Shp2. The
receptor Y1 phosphorylation results shown in Fig. 2 are plotted as a function
of the fraction of receptor dimers bound with at least one Shp2 (bD). Plotted
in this way, the results may be compared with the predictions of a simpliﬁed,
two-parameter model (Materials and Methods, Eq. 3). One parameter in this
model, f, was determined from the value of pYR/Rtot at bD  1. The value
of the other, the exchange quotient Q, determines the degree of serial
engagement, the ability of an Shp2 molecule to engage and dephosphorylate
numerous receptor complexes for each instance of Y1 phosphorylation (solid
curves). The values of Q, in descending order, are 1, 0.97, 0.81, 0.51, and 0.
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taken as a lumped parameter in our simpliﬁed kinetic model
(Eq. 3). Thus, when koff is low or xr are high, Shp2 binding
to receptors is approximately stoichiometric (Fig. 4 a). When
koff is higher and xr are modest, Shp2 binds with lower
avidity, and there is also the opportunity for serial engage-
ment when activated receptors outnumber Shp2 molecules
(Fig. 4 c).
Deletion of the Shp2 N-SH2 domain can diminish
or enhance Shp2 function; C-terminal
phosphorylation of Shp2 mimics N-SH2 deletion
Based on dephosphorylation of generic phosphorylated
substrates in solution, it is clear that deletion of the N-SH2
domain releases the autoinhibition of the PTP catalytic site,
yielding full catalytic activity of the Shp2 enzyme. Based on
the cooperation of the two SH2 domains in targeting Shp2 to
activated receptors and other signaling complexes at the
plasma membrane, however, it is not immediately apparent
how this modiﬁcation would affect dephosphorylation of
substrates associated with those complexes and thus mod-
ulation of signal transduction by Shp2 in cells.
Indeed, model calculations show that deletion of the N-SH2
can either diminish or enhance the dephosphorylation of a
targeted substrate such as a receptor phosphorylation site
(Fig. 5). The absence of the N-SH2 domain enhances the
activity of Shp2 while associated with receptors through its
C-SH2 domain, but at the same time it affects the avidity of the
Shp2/receptor interaction. The calculations show that, under
the conditions where activated receptors are predominantly
associated with full-length Shp2, N-SH2 deletion tends to di-
minish substrate dephosphorylation; conversely, when either
the activated receptors are in excess over Shp2 or the SH2
domain/receptor interactions yield a relatively low avidity,
N-SH2 deletion can enhance substrate dephosphorylation
(Fig. 5 a–c). Based on the concepts established in the previous
section, it is clear that there are two distinct effects that contrib-
ute to the enhancement offered by N-SH2 deletion: the lack of
PTP autoinhibition and the serial engagement of receptors as
the lifetime of Shp2/receptor complexes is decreased.
To further illustrate the importance of the parameter values
on the predicted effect of N-SH2 deletion in Shp2 signaling,
the SH2 domain afﬁnities were adjusted to a relatively low
value (KD ¼ 5 mM, as in Fig. 5 c) while both increasing the
catalytic rates of receptor Y1 phosphorylation and dephos-
phorylation by 10-fold (to negate the serial engagement
effect) and increasing the rates of all intracomplex associa-
tions by 100-fold (Fig. 5 d). Under these conditions, the full-
length Shp2 is capable of high-avidity binding to activated
receptors, even though the afﬁnities of the individual SH2
domains are low. It is clear that N-SH2 deletion compromises
Shp2 function under these conditions, particularly when Shp2
molecules outnumber activated receptors.
As illustrated in Fig. 1 e, the base model was extended
to include phosphorylation of receptor-bound Shp2 on its
C-terminal tail; this phosphorylation site may then engage the
N-SH2 domain, which prevents N-SH2 from either auto-
inhibiting the PTP domain or participating in receptor
binding. While engaged in this manner, Shp2 functions as
FIGURE 4 Intracomplex binding is important for high-avidity binding
of Shp2. The fraction of activated receptors phosphorylated on the Shp2
substrate site, Y1 (pYR/Rtot), was calculated as a function of the abundance of
activated receptors (Rtot) and the intracomplex association rate constants
(varied by multiplying the base-case values of xr, listed in Table 2, by a
common factor). The value of koff,CSH2 ¼ koff,NSH2 ¼ koff was varied ac-
cording to (a) koff¼ 0.1 s1; (b) koff¼ 1.0 s1; (c) koff¼ 5.0 s1. In all cases,
Stot ¼ 0.10 mM, and other parameter values are as listed in Table 1.
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it does when N-SH2 is deleted altogether. Accordingly, the
output of the extended model with Shp2 phosphorylation is
invariably bracketed by the results of the base model for full-
length and N-SH2-deleted Shp2 (Fig. 5), depending on the
relative extent of Shp2 phosphorylation and whether the Shp2
phosphorylation site or activated receptors better compete for
N-SH2 binding. The model therefore predicts that, in the
same fashion as N-SH2 deletion, tyrosine phosphorylation of
Shp2 can either diminish or enhance Shp2-mediated dephos-
phorylation of receptor-associated substrates.
Deletion of the Shp2 C-SH2 domain, or of both
SH2 domains, compromises Shp2 function
With its C-SH2 domain deleted, Shp2 remains autoinhibited
by its N-SH2, and any receptor engagement must occur
while Shp2 is in the open conformation. Even with the SH2
domain KD skewed toward the highest afﬁnity (0.1 mM,
comparable with the concentrations of Shp2 and activated
receptors), the autoinhibition drastically reduces the rate of
Shp2-receptor association when C-SH2 is absent. Thus, only
a small fraction of activated receptors are associated with and
dephosphorylated by C-SH2-deleted Shp2 (Fig. 6 a). For
lower SH2 domain afﬁnities (KD up to 10 mM) as well, it was
conﬁrmed that C-SH2 deletion always diminishes receptor
dephosphorylation, despite the greater degree of serial
engagement. If one swaps the frequencies of the open and
close transitions, such that the open conformation is highly
favored, the performance is nearly identical to the N-SH2
deletion mutant (Fig. 6 a and results not shown).
Like the C-SH2 deletion, truncation of both SH2 domains
yields an Shp2 variant that is deﬁcient in dephosphorylating
receptors but for a different reason. Whereas the C-SH2
deletion has reduced targeting capability and full auto-
inhibition of the PTP, deletion of both SH2 domains yields a
fully active enzyme in solution but erases all targeting
capability in cells. Which of these deﬁciencies is more
debilitating for the Shp2 function depends on the binding and
catalytic properties of the enzyme (Fig. 6 b). For the set of
parameter values considered here, the catalytic efﬁciency of
the SH2-null variant is sensitive to a change in the catalytic
rate constant, kcat,PTP. In contrast, for C-SH2-deleted Shp2,
the cooperative binding of the N-SH2 and PTP domains
gives rise to a scenario in which the lifetime of the Shp2/
receptor complex is essentially limited by the PTP catalytic
step, and the extent of dephosphorylation is thus determined
by the rate of Shp2-receptor association.
Evaluation of restrictive binding rules for
PTP-substrate binding within the complex
Our model considers all of the possible ways the two SH2
domains and PTP domain of Shp2 may participate in inter-
actions with activated receptors. The multiplication factors
for intracomplex binding, xr, were arbitrarily assigned
different values to illustrate the generality of the model
(Table 2), but currently there is no reason to suspect that
certain modes of intracomplex binding would be favored or
disfavored. One can, however, assess the possible impact of
structural constraints on the dephosphorylation of receptor-
associated substrates (Fig. 7).
FIGURE 5 Conﬂicting roles of the N-SH2 domain in
Shp2 autoinhibition and receptor targeting. The base
model was modiﬁed to exclude all binding interactions
of the N-SH2 domain, and the function of N-SH2-deleted
Shp2 (circles) was compared with full-length Shp2
(squares) for various levels of activated receptors and an
Shp2 expression level of Stot ¼ 0.10 mM. An extended
model shows that receptor-mediated phosphorylation of
Shp2, which occupies the N-SH2 in an intramolecular
fashion, yields an intermediate level of receptor dephos-
phorylation (stars). The SH2 dissociation rate constant,
koff,CSH2 ¼ koff,NSH2 ¼ koff was varied according to (a) koff
¼ 0.1 s1; (b) koff¼ 1.0 s1; (c and d) koff¼ 5.0 s1. Other
rate constant values are as listed in Tables 1 and 2. In d, the
values of kkin,Y1 and kcat,PTP were increased 10-fold, and all
intracomplex association rates were increased 100-fold.
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For instance, if Shp2 with only one SH2 domain bound
is to dephosphorylate the receptor, the PTP may be restricted
to binding only one of the two receptors in the dimer. This is
of little consequence for full-length Shp2, because simulta-
neous binding of both SH2 domains is greatly favored (Fig. 7
a). On the other hand, when one of the SH2 domains is
deleted, this restriction diminishes receptor dephosphoryla-
tion signiﬁcantly; under these conditions, N-SH2 deletion
would be less likely to enhance Shp2 function relative to the
full-length enzyme (Fig. 7 b). Conversely, when both of its
SH2 domains are bound, full-length Shp2 is compromised if
its PTP domain is constrained to binding only one of the
receptors (e.g., whichever receptor is bound to C-SH2, Fig. 7
c), whereas this restriction is not applicable to N-SH2-
deleted Shp2. Given the dynamic interactions between full-
length Shp2 and a receptor dimer, it is still possible in this
case for the PTP domain to interact with the substrate sites of
both receptors before dissociating from the complex com-
pletely, but it does so with greatly reduced proclivity.
DISCUSSION
The function of a signaling protein is generally pieced to-
gether from structural analysis, through the identiﬁcation of
homologous domains and their arrangement in the protein’s
tertiary structure, and biochemical characterization of bind-
ing speciﬁcities and afﬁnities in solution. In the case of Shp2,
an SH2 domain-containing PTP, a consistent story has thus
emerged. Full-length Shp2 tends to adopt a closed, auto-
inhibited conformation that blocks the active site of the PTP;
stabilization of the fully active, open conformation of Shp2
requires the occupancy of its N-SH2 domain, either by
tyrosine-phosphorylated proteins/peptides or by one of two
tyrosine phosphorylation sites in the C-terminal tail of Shp2
itself. The function of Shp2 in cells adds another dimension
of complexity, namely that the SH2 domains are also impor-
tant for targeting Shp2 to signaling complexes, where the
PTP enjoys an induced proximity effect. To synthesize and
analyze such dynamics in signal transduction, kinetic
modeling has become an increasingly valuable tool, but the
numerous combinations of binding and phosphorylation
states impose a signiﬁcant technical challenge. The rule-
based approach employed here permitted us to examine how
multiple protein domains with different functionalities work
in concert to affect signaling function.
The central feature of our model is the cooperative binding
of the two SH2 domains of Shp2. We assume binding to
symmetric phosphorylation sites on a pair of dimerized
receptors, but the conclusions are expected to be sufﬁ-
ciently general. Experiments with individual or tandem SH2
FIGURE 6 The C-SH2 domain is essential for receptor
targeting of Shp2. The base model was modiﬁed to exclude all
binding interactionsof theC-SH2domainor of both theC-SH2
and N-SH2 domains. Receptor dephosphorylation was as-
sessed for various levels of activated receptors and koff,NSH2¼
0.1 s1. Except where indicated, all other rate constant values
are as listed inTables 1 and 2. (a)Defective Shp2 functionwith
C-SH2 deleted (solid symbols). Shp2 concentration Stot values
are as indicated. Shift of the open/close equilibrium to favor the
open conformation (open symbols)mimics theN-SH2deletion
case. (b) Comparison of C-SH2 deletion (solid symbols) with
deletion of both SH2 domains (open symbols) for different
values of the PTP catalytic rate constant, kcat.
FIGURE 7 Potential restrictions on PTP-substrate binding within the complex. Certain of the multiplication factors, xr, were assigned either base values
(Table 2; black) or a value of zero (red) to assess the corresponding modes of PTP-Y1 interaction after binding of one or both SH2 domains of Shp2: (a) xr3 ¼
xr4 ¼ 103 or 0 mM; (b) same as a but with N-SH2-deleted Shp2; (c) xr7 ¼ 100 or 0 mM. In all cases, Stot ¼ 0.10 mM, and SH2 dissociation rate constant
(koff,CSH2 ¼ koff,NSH2 ¼ koff) values are as indicated.
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domains of Shp2 and singly or doubly phosphorylated
peptides show that the interaction of both SH2 domains,
which individually possess low single-site afﬁnities (KD ;
1–10 mM), yields a high overall binding avidity (effective
KD ; 1–10 nM) that could be sufﬁcient for near stoichio-
metric binding in cells (18–20). A 1,000-fold enhancement
in binding translates to a value of xr that is roughly 1,000
times higher than the single-site KD, or xr ; 1–10 mM, in
line with our conservative estimates. In the context of full-
length Shp2, to the extent that N-SH2 cannot bind to phos-
photyrosine while in the closed conformation, the value of xr
would need to be even higher to overcome this effect (see
Figs. 4 c and 5 d). When Shp2 binding avidity is not as
strong, we found that the effect of serial engagement can at
least partially compensate; this effect arises when encounters
between Shp2 and receptors are ﬂeeting relative to the rate of
substrate phosphorylation/dephosphorylation (Fig. 3).
The disparity between afﬁnity and avidity of the Shp2
SH2 domains is at the core of what is perhaps our most
interesting ﬁnding: that deletion of the N-SH2 domain can
either diminish or enhance receptor dephosphorylation (Fig.
5). Under conditions that favor cooperative binding of a high
fraction of receptors, N-SH2 deletion tends to abrogate Shp2
function; otherwise, Shp2 function may be enhanced. Inter-
estingly, the effect of N-SH2 deletion can be reversed as the
number of activated receptors is modulated, as by a change
in growth factor/cytokine concentration or by receptor over-
expression/knock-down.
These predictions of the model can be related to published
data, although it should be noted that those data do not allow
for a quantitative comparison. Targeted deletion of Shp2
exon 3 in mouse yields expression of a mutant Shp2 with
most of its N-SH2 domain deleted. As expected, this muta-
tion yields greater overall PTP activity as measured in
solution, but the Shp2 variant is severely defective in binding
to activated receptors and other signaling complexes (46–
50). The effect of this mutation on intracellular signal
transduction was assessed at the level of growth factor-
stimulated Erk activation, which is positively modulated by
Shp2, with variable results. In one study, Erk phosphory-
lation stimulated by PDGF was enhanced in the mutant cells
relative to wild-type, despite a lower expression level
(;25% of wild-type) of the mutant, whereas Erk signaling
stimulated by ﬁbroblast growth factor was signiﬁcantly
reduced in the same cells (46). In another study using the
same deletion of Shp2 exon 3, Erk signaling stimulated by all
growth factors tested, including PDGF, was diminished in
mutant-expressing cells (48). These disparate observations
are not inconsistent with our modeling results, which predict
that different receptor expression levels and/or Shp2 binding
avidities can affect the outcome of N-SH2 deletion. Alterna-
tively, some receptors may activate Shp2 for dephosphor-
ylating substrates not intimately associated with the complex,
in which case targeting of Shp2 with N-SH2 deleted is not
necessary.
By comparison with N-SH2 deletion, certain Shp2 muta-
tions disrupt autoinhibition of the PTP without preventing
binding of phosphorylated peptides to N-SH2; indeed, favor-
ing the open conformation enhances this function. Interest-
ingly, such activating Shp2 mutation sites are associated with
Noonan’s syndrome, a common human birth defect (51).
Expression of Shp2 variants activated in this manner gen-
erally yields enhanced growth factor stimulation of Erk signal-
ing, at least in certain cell contexts, arguing for the importance
of the N-SH2 targeting function (52–56).
Our modeling approach also sheds light on the most
controversial aspect of Shp2 regulation, the mechanism by
which Shp2 phosphorylation modulates its activity and
signaling functions. In our extended model, Shp2 phospho-
rylation at one site and the intramolecular binding of N-SH2
were considered. As one might have predicted, this gives a
level of receptor dephosphorylation that lies between those
mediated by full-length, unphosphorylated Shp2 and Shp2
with N-SH2 deleted (Fig. 5). In other words, intramolecular
binding of N-SH2 mimics N-SH2 deletion in our model.
What if we had included both of the Shp2 phosphorylation
sites? Biochemical evidence suggests that these sites can
engage both SH2 domains, favoring the open conformation
of Shp2 in a cooperative manner (26). If so, it is clear that
inclusion of both phosphorylation sites would mimic the dele-
tion of both SH2 domains; such a mechanism discounts any
targeting function of the SH2 domains. Alternative mecha-
nisms for the effect(s) of Shp2 phosphorylation include bind-
ing the adaptor protein Grb2, which might help target Shp2
to Gab1 in signaling by EGF receptor and other RTKs (57),
and binding of SH2 domain-containing substrates of Shp2
(24).
This modeling study underscores the complexity of
interactions between signaling proteins with multiple mod-
ular domains. In the case of Shp2, it illustrates the potential
tradeoffs between regulation of catalytic activity and target-
ing of the enzyme to substrate-containing complexes or com-
partments, and it shows that intracellular Shp2 and receptor
expression levels must be carefully considered in the inter-
pretation of cell signaling experiments. Conversely, these
expression levels would need to be measured and varied
systematically if the quantitative predictions of the model are
to be validated. Rule-based kinetic modeling is a powerful
computational tool for modeling the assembly of signaling
complexes and signal transduction pathways, and here we
have shown how it can be used to impart structure-based
functionality to their molecular components.
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